201 related articles for article (PubMed ID: 38212123)
1. Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancer.
Guler GD; Ning Y; Coruh C; Mognol GP; Phillips T; Nabiyouni M; Hazen K; Scott A; Volkmuth W; Levy S
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212123
[TBL] [Abstract][Full Text] [Related]
2. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
3. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
4. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD
Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Frigola J; Navarro A; Carbonell C; Callejo A; Iranzo P; Cedrés S; Martinez-Marti A; Pardo N; Saoudi-Gonzalez N; Martinez D; Jimenez J; Sansano I; Mancuso FM; Nuciforo P; Montuenga LM; Sánchez-Cespedes M; Prat A; Vivancos A; Felip E; Amat R
Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
[TBL] [Abstract][Full Text] [Related]
6. Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.
Carbonell C; Frigola J; Pardo N; Callejo A; Iranzo P; Valdivia A; Priano I; Cedrés S; Martinez-Marti A; Navarro A; Lenza L; Soleda M; Gonzalo-Ruiz J; Vivancos A; Sansó M; Carcereny E; Morán T; Amat R; Felip E
Mol Oncol; 2023 May; 17(5):779-791. PubMed ID: 36852704
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients.
Zhou X; Li C; Zhang Z; Li DY; Du J; Ding P; Meng H; Xu H; Li R; Ho E; Zhang A; Okunieff P; Lu J; Sha MY
Sci Rep; 2021 Apr; 11(1):7633. PubMed ID: 33828112
[TBL] [Abstract][Full Text] [Related]
8. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cortellini A; Ricciuti B; Borghaei H; Naqash AR; D'Alessio A; Fulgenzi CAM; Addeo A; Banna GL; Pinato DJ
Cancer; 2022 Aug; 128(16):3067-3079. PubMed ID: 35727053
[TBL] [Abstract][Full Text] [Related]
9. Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.
Jiang T; Li X; Wang J; Su C; Han W; Zhao C; Wu F; Gao G; Li W; Chen X; Li J; Zhou F; Zhao J; Cai W; Zhang H; Du B; Zhang J; Ren S; Zhou C; Yu H; Hirsch FR
Theranostics; 2017; 7(19):4753-4762. PubMed ID: 29187901
[No Abstract] [Full Text] [Related]
10. Discovery of efficacy biomarkers for non-small cell lung cancer with first-line anti-PD-1 immunotherapy by
data-independent acquisition mass spectrometry.
Chao Y; Jiang W; Wang X; Wang X; Song J; Chen C; Zhou J; Huang Q; Hu J; Song Y
Clin Exp Immunol; 2022 May; 208(1):60-71. PubMed ID: 35348622
[TBL] [Abstract][Full Text] [Related]
11. Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab.
Mondelo-Macía P; García-González J; León-Mateos L; Anido U; Aguín S; Abdulkader I; Sánchez-Ares M; Abalo A; Rodríguez-Casanova A; Díaz-Lagares Á; Lago-Lestón RM; Muinelo-Romay L; López-López R; Díaz-Peña R
Mol Oncol; 2021 Nov; 15(11):2923-2940. PubMed ID: 34465006
[TBL] [Abstract][Full Text] [Related]
12. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing.
Yu Y; Qian J; Shen L; Ji W; Lu S
Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer.
Cho JW; Hong MH; Ha SJ; Kim YJ; Cho BC; Lee I; Kim HR
Exp Mol Med; 2020 Sep; 52(9):1550-1563. PubMed ID: 32879421
[TBL] [Abstract][Full Text] [Related]
14. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
[TBL] [Abstract][Full Text] [Related]
16. One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer.
Lee Y; Cho Y; Park EY; Park SY; Hwang KH; Han JY
Oncologist; 2021 Oct; 26(10):e1683-e1692. PubMed ID: 34272914
[TBL] [Abstract][Full Text] [Related]
17. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
18. 5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapy.
Li Q; Huang CC; Huang S; Tian Y; Huang J; Bitaraf A; Dong X; Nevalanen MT; Zhang J; Manley BJ; Park JY; Kohli M; Gore EM; Kilari D; Wang L
medRxiv; 2023 Oct; ():. PubMed ID: 37904926
[TBL] [Abstract][Full Text] [Related]
19. A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.
Del Re M; Cucchiara F; Rofi E; Fontanelli L; Petrini I; Gri N; Pasquini G; Rizzo M; Gabelloni M; Belluomini L; Crucitta S; Ciampi R; Frassoldati A; Neri E; Porta C; Danesi R
Cancer Immunol Immunother; 2021 Jun; 70(6):1667-1678. PubMed ID: 33315149
[TBL] [Abstract][Full Text] [Related]
20. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]